

Appl. No. 10/798,198  
Amdt. dated March 6, 2006  
Reply to Office Action of February 6, 2006


### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

The claimed invention is:

Claim 1 (Original): A compound of formula (I):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

$\text{R}^1$  is H;

$\text{R}^2$  is a substituted or unsubstituted  $(\text{C}_1\text{-C}_8)$ alkyl,  $(\text{C}_3\text{-C}_7)$ cycloalkyl,  $(\text{C}_3\text{-C}_9)$ aryl,  $(\text{C}_3\text{-C}_9)$ heteroaryl, amide, amino,  $(\text{C}_1\text{-C}_8)$ alcohol,  $(\text{C}_3\text{-C}_9)$ heterocycloalkyl,  $(\text{C}_1\text{-C}_8)$ alkyl $(\text{C}_3\text{-C}_9)$ aryl,  $(\text{C}_1\text{-C}_8)$ alkylamine,  $(\text{C}_1\text{-C}_8)$ alkylamide; or  $\text{R}^1$  and  $\text{R}^2$  taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl;

$\text{R}^3$  is independently selected from the group consisting of H,  $(\text{C}_1\text{-C}_8)$ alkyl, halo,  $(\text{C}_1\text{-C}_8)$ alkoxy, sulfonyl, cyano, and keto;

$n$  is an integer from 0-5;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.


Claim 2 (Original): A compound of claim 1, wherein  $\text{R}^3$  is H, bromo, chloro, cyano, methoxy,  $(\text{C}_1\text{-C}_8)$ alkyl- $\text{SO}_2$ -, or  $(\text{C}_1\text{-C}_8)$ alkyl $\text{C}(=\text{O})$ -.

Claim 3 (Original): A compound of claim 1, wherein  $n$  is 0-4.

Appl. No. 10/798,198  
Amdt. dated March 6, 2006  
Reply to Office Action of February 6, 2006

Claim 4 (Original): A compound of claim 3, wherein  $n$  is 0-1.

Claim 5 (Withdrawn): A compound of formula (II):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

$\text{R}^1$  is H;


$\text{R}^2$  is a substituted or unsubstituted ( $\text{C}_1\text{-C}_8$ )alcohol, ( $\text{C}_3\text{-C}_9$ )cycloalkyl, ( $\text{C}_3\text{-C}_9$ )heterocycloalkyl, ( $\text{C}_3\text{-C}_9$ )heteroaryl, ( $\text{C}_1\text{-C}_8$ )alkylamine, ( $\text{C}_1\text{-C}_8$ )alkyl( $\text{C}_3\text{-C}_9$ )aryl, or ( $\text{C}_1\text{-C}_8$ )alkylamide; or  $\text{R}^1$  and  $\text{R}^2$  taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl group;

Het is a substituted or unsubstituted heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

Claim 6 (Withdrawn): A compound of claim 5, wherein Het is a substituted or unsubstituted ( $\text{C}_5\text{-C}_{10}$ )heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

Claim 7 (Withdrawn): A compound of claim 6, wherein Het is a substituted or unsubstituted furanyl, thienyl, pyridyl, or benzofuranyl group.

Claim 8 (Withdrawn): A compound of formula (III):



Appl. No. 10/798,198  
Amdt. dated March 6, 2006  
Reply to Office Action of February 6, 2006

or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R<sup>1</sup> is H;

R<sup>2</sup> is a substituted or unsubstituted (C<sub>1</sub>-C<sub>8</sub>)alcohol;

Ar is a substituted or unsubstituted (C<sub>3</sub>-C<sub>9</sub>)aryl group;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

Claim 9 (Withdrawn): A compound of claim 8, wherein R<sup>2</sup> is a substituted or unsubstituted (C<sub>1</sub>-C<sub>5</sub>)alcohol.

Claim 10 (Withdrawn): A compound of claim 9, wherein R<sup>2</sup> is a substituted or unsubstituted (C<sub>3</sub>-C<sub>5</sub>)alcohol.

Claim 11 (Withdrawn): A compound of claim 8, wherein Ar is a substituted or unsubstituted naphthyl group.

Claim 12 (Withdrawn): A pharmaceutical composition comprising a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier.

Claim 13 (Withdrawn): A method of preventing or treating a TGF-related disease state in a mammal (animal or human) comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1-11 to the animal or human suffering from the TGF-related disease state.

Claim 14 (Withdrawn): A method of claim 13, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

Claim 15 (New): A compound of claim 1 wherein

R<sup>2</sup> is a substituted or unsubstituted (C<sub>1</sub>-C<sub>8</sub>)alkyl(C<sub>3</sub>-C<sub>9</sub>)aryl;

Appl. No. 10/798,198  
Amdt. dated March 6, 2006  
Reply to Office Action of February 6, 2006

$R^3$  is independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>8</sub>)alkyl, halo, (C<sub>1</sub>-C<sub>8</sub>)alkoxy, sulfonyl, cyano, and keto; and  
n is 0-4.

Claim 16 (New): A compound of claim 15, where  $R^3$  is independently selected from the group consisting of H, or bromo, chloro, and methoxy.

Claim 17 (New): A compound of claim 16 wherein n=0 and  $R^2$  is an unsubstituted (C<sub>1</sub>-C<sub>8</sub>)alkyl(C<sub>3</sub>-C<sub>9</sub>)aryl.

Claim 18 (New): A compound of claim 17 wherein said (C<sub>1</sub>-C<sub>8</sub>)alkyl(C<sub>3</sub>-C<sub>9</sub>)aryl is CH<sub>2</sub> phenyl.

Claim 19 (New): The compound 3-amino-6-phenyl-pyrazine-2-carboxylic acid benzylamide.